← Back to headlines
RBC Reiterates Outperform Rating for Merck (MRK) Amid Investor Concerns
RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Italy Extends Diesel Fuel Tax Cut Through Early September
21m ago
Cisco Abandons Traditional Hardware Restrictions to Pursue AI Infrastructure Boom
31m ago
Executives at Itron and Lyft Sell Significant Company Stock Holdings
33m ago
Senior Official Firmly Rejects External Political Pressure and Influence Attempts
33m ago